| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-02-26 | tenofovir alafenamide (TAF) | HIV-1 infection | 3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2015-02-26 | Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) | genotypes 1 or 4 chronic hepatitis C virus (HCV) infection among patients co-infected with HIV |
3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2015-02-26 | daclatasvir and sofosbuvir | patients with chronic hepatitis C virus (HCV) coinfected with HIV |
3 | BMS (USA - NY) | Infectious diseases |
| 2015-02-25 | Provenge® (sipuleucel-T) | biochemically-recurrent prostate cancer (BRPC) |
2 | Valeant Pharmaceuticals | Cancer - Oncology |
| 2015-02-25 | GS-9620 | HIV infection |
preclinical | Gilead Sciences (USA - CA) | Infectious diseases |
| 2015-02-24 | apatorsen (OGX-427) | advanced, non-squamous, non-small cell lung cancer (NSCLC) | 2 | OncoGenex Pharmaceuticals (USA - WA) Sarah Cannon Research Institute (USA - TX) | Cancer - Oncology |
| 2015-02-24 | ALKS 7106 | pain |
1 | Alkermes (Ireland) | CNS diseases |
| 2015-02-20 | OG217SC - oral formulation of semaglutide | type 2 diabetes | 2 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2015-02-19 | Ebola GP Vaccine (Ebola virus glycoprotein (GP) recombinant nanoparticle vaccine candidate adjuvanted with Matrix-M™) | Ebola fever |
1 | Novavax (USA - MD) | Infectious diseases |
| 2015-02-19 | ADX92639 | preclinical | Addex Therapeutics (Switzerland) | Neurodegenerative diseases - Neurological diseases | |
| 2015-02-18 | PLX-R18 cells (PLacental eXpanded RAD (PLX-RAD) cells) | acute radiation syndrome |
Pluristem Therapeutics (Israel) National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) (USA) | Hematologic diseases | |
| 2015-02-18 | Lymphoseek® (technetium Tc 99m tilmanocept) | sentinel lymph node biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity |
Navidea Biopharmaceuticals (USA - OH) | Cancer - Oncology | |
| 2015-02-18 | Reolysin® (pelareorep - human reovirus type 3 Dearing strain) | advanced or metastatic colorectal cancer |
2 | Oncolytics Biotech (Canada) | Cancer - Oncology |
| 2015-02-17 | Cerdelga® (eliglustat tartrate) | Gaucher disease |
3 | Genzyme (USA - MA), a Sanofi company (France) | Rare diseases - Genetic diseases |
| 2015-02-17 | pegylated recombinant human hyaluronidase PH20 - PEGPH20 | preclinical | Halozyme Therapeutics (USA - CA) | Cancer - Oncology | |
| 2015-02-17 | SEA-CD40 | advanced solid tumors |
1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2015-02-17 | motesanib | stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC) |
3 | Takeda Pharmaceutical (Japan) | Cancer - Oncology |
| 2015-02-17 | VB-201 | psoriasis | 2 | VBL Therapeutics (Israel) | Autoimmune diseases - Dermatological diseases |
| 2015-02-17 | VB-201 | ulcerative colitis | 2 | VBL Therapeutics (Israel) | Autoimmunes diseases - Inflammatory diseases |
| 2015-02-16 | MultiStem® | ischemic stroke | 2 | Athersys (USA - OH) | Cerebrovascular diseases |
